CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Summary

Relapsed/refractory leukemia and lymphoma lack effective treatment. The cancer immunotherapy with chimeric antigen receptor (CAR) T cells provides a potent new approach for them. In this clinical trial, the investigators aim to assess the safety and efficacy of administering T cell expressing an anti-CD19 CARs to patients with chemotherapy resistant or refractory CD19 positive B cell malignancy including leukemia and lymphoma.

Timeline

Start

2015-07

Primary completion

2020-06

Completion

2020-06

Publications

• Hou M, Zhang W, Qi Z, Li G, Mei H, Qi S, Jin R, Zhao Y, Tang X, Xiu B, Chen X, Zhao Y, Hu C, Qian C, Li X, Xu Z, Chen Y, Wu C, Wang B, Yan L, Li D, Huang Y, Liang R, Wang A, Liu J, Wang W, Li B, Long J, Li P, Liang A, Liu Q, Yang J. Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs. Nat Commun. 2026 Mar 31;17(1):3045. doi: 10.1038/s41467-026-70867-5.

Drugs

Indications